An Artificial Intelligence model showed improvement in type 2 diabetes remission rates, according to a study by the American Diabetes Association (ADA).
Remission for patients with type 2 diabetes is defined in the study as "maintaining normal blood glucose levels for at least three months without taking diabetes medication." Remission rates are assessed through changes in hemoglobin A1C, so the researchers conducted a trial to measure the benefits of Artificial Intelligence (AI) technology, and compare it to traditional care.
Twin Precision Treatment (TPT) technology was compared with standard care at 90-day intervals. In total, 319 patients living with type 2 diabetes, and with an average age of 45 years, took part in the study. One of the characteristics of the patients was that they had been diagnosed with diabetes for an average of 3.9 years and had an A1C of 9% at the start of the randomized trial.
The TPT intervention is a predictive analysis that uses AI and devices to collect data from patients, such as aspects of nutrition, physical activity, breathing and sleep.
Of the total number of patients, 262 managed to complete the 180-day trial, of whom 199 received the TPT intervention and 63 the standard intervention. Of the 199 patients belonging to TPT, almost 95% reached A1C levels lower than 6.5%, without the need to take specific medications for diabetes. And 84% achieved remission rates that match ADA criteria. Some patients even stopped taking insulin because their glucose levels had reached normal levels.
“Our results demonstrate the potential of Whole-Body Digital Twin technology to change conventional drug-based management of type 2 diabetes to achieve remission of type 2 diabetes with drug-free living,” explained Dr. Paramesh Shamanna , who is medical director of Twin Health and was the lead author of the study.
